Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML

Om avsnittet

In this week’s episode we’ll discuss the findings from a study exploring the combination of concurrent pembrolizumab, adriamycin, vinblastine, and dacarbazine in newly diagnosed classical Hodgkin lymphoma, learn more about the effects of targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and review the findings from a study aimed at improving the bone marrow homing of CAR-cytokine induced killer cells in AML.

Om avsnittet

Fler avsnitt

Designing Durable Remissions in Relapsed AML and Follicular Lymphoma

Dose Makes the Cure: Venetoclax in Ph- ALL

Exploiting Vulnerabilities in High‑Risk MM and Mapping the Red Cell Interactome

MYB driven ALL and Venetoclax-Azacitidine damage to Bone Marrow

Predictive Markers of Glofitamab Resistance in R/R B-NHL

Better Together: Adding daratumumab for AL Amyloidosis and and Mezigdomide for MM

Balancing Infection and Thrombosis: Bispecific Antibodies and the Many Roles of HRG

Cost-Effectiveness of Current SCD Treatments and Potential Therapeutic Targets for Fetal Hemoglobinopathies

HLH-like toxicities after CAR-T and Structure-Function Relationships of FNAIT

FLT3-ITD microclones in AML and Results from the RESET-PV trial